Quick Answer
Arcturus Therapeutics Holdings Inc. reported Net Income Loss of -$65.78 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +18.7% in Net Income Loss from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Net Income Loss has declined by 202.0%.
- Historical annual values: Fiscal year 2025: -$65.78 million | Fiscal year 2024: -$80.94 million | Fiscal year 2023: -$29.73 million | Fiscal year 2022: $9.35 million | Fiscal year 2021: -$203.67 million | Fiscal year 2020: -$72.15 million | Fiscal year 2019: -$25.99 million | Fiscal year 2018: -$21.79 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: